|
(AFX UK Focus)
2007-11-20 16:31
Bristol-Myers, Osuka get FDA ok for Abilify as add-on depression treatment |
|---|
| Article layout: raw |
|
NEW YORK (Thomson Financial) - Bristol-Myers Squibb Co. Tuesday said it and partner Osuka Pharmaceutical Co. have received approval of a supplemental new drug application for the use of Abilify as an add-on treatment for depression from the Food and Drug Adminstration. The company said Abilify is the first medication to receive FDA approval as an adjunct treatment for adults with major depressive disorder. Shares of Bristol-Myers rose 1.5% to $28.44 in late morning trades. Michael Baron mb
COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News. |
| Re-organisations, re-structurings, name changes, AGM, EGM |
| Article layout: raw |
|